ERYTECH's Lead AML Drug Flunks Phase II Test Post author:Sam Post published:December 7, 2017 Post category:BioPharma The study enrolled a total of 123 patients at 30 European sites. Source: BioSpace You Might Also Like Ethicon Release: Company Announces Acquisition Of MEGADYNE January 19, 2017 Watch Out! Novartis AG Hungry for Small Takeover Targets With Early-Stage Drugs January 24, 2017 Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Disease… December 4, 2017
Fortress Biotech Forms Subsidiary Tamid Bio to Develop Novel AAV Gene Therapies in Orphan Disease… December 4, 2017
